These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 32818555)
1. Peritransplantation Use of Ruxolitinib in Myelofibrosis. Ibrahim U; Petrone GEM; Mascarenhas J; Keyzner A Biol Blood Marrow Transplant; 2020 Dec; 26(12):2177-2180. PubMed ID: 32818555 [TBL] [Abstract][Full Text] [Related]
2. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis. Wang Z; Jin X; Zeng J; Xiong Z; Chen X Ann Hematol; 2024 Sep; 103(9):3293-3301. PubMed ID: 38494551 [TBL] [Abstract][Full Text] [Related]
3. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926 [TBL] [Abstract][Full Text] [Related]
4. Practical management of myelofibrosis with ruxolitinib. Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193 [TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Harrison CN; Talpaz M; Mead AJ Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690 [TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545 [TBL] [Abstract][Full Text] [Related]
7. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520 [TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Vaddi K; Sarlis NJ; Gupta V Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187 [TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib. Becker H; Engelhardt M; von Bubnoff N; Wäsch R Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Gupta V; Hari P; Hoffman R Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib. Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628 [TBL] [Abstract][Full Text] [Related]
13. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053 [TBL] [Abstract][Full Text] [Related]
15. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851 [TBL] [Abstract][Full Text] [Related]
16. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598 [TBL] [Abstract][Full Text] [Related]
17. Janus activated kinase inhibition in myelofibrosis. Malhotra H Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141 [TBL] [Abstract][Full Text] [Related]
18. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576 [TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Verstovsek S Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678 [TBL] [Abstract][Full Text] [Related]
20. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. Tiribelli M; Palandri F; Sant'Antonio E; Breccia M; Bonifacio M Bone Marrow Transplant; 2020 Apr; 55(4):708-716. PubMed ID: 31534197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]